Checkpoint Therapeutics Announces FDA Acceptance of Bla Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma
checkpoint therapeutics宣佈,美國FDA接受了科西貝利單抗用於治療晚期鱗狀細胞癌的BLA重新提交申請。
Checkpoint Therapeutics Announces FDA Acceptance of Bla Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma
checkpoint therapeutics宣佈,美國FDA接受了科西貝利單抗用於治療晚期鱗狀細胞癌的BLA重新提交申請。
譯文內容由第三人軟體翻譯。